Neurotech International (ASX:NTI)
Autism Trial Results a Major Boost for NTI’s Proprietary Tech & Children with Autism
Jul 10, 2018
Leading medical device company Neurotech International (ASX:NTI) this week reported highly promising results from US clinical trials of its Mente autism device.
Related Neurotech International (ASX:NTI) articles
Revolutionary MedTech Device: a New Frontier in Autism Treatment
Jun 26, 2018
Today’s company has created the first and only regulated medical device for the management of autism in a home setting.
The Next Big Thing in Nickel? ASX Newcomer Partners Up with World’s Biggest Stainless Steelmaker
Jan 15, 2019
Diversified ASX Junior Next Door to Fortescue May Have a Major Australian Gold Asset
Jan 14, 2019